The largest study to date evaluating the impact of circulating lymphoma cells (CL) on outcomes in patients with newly diagnosed de novo diffuse large B-cell lymphoma (DLBCL) found that presence of CL at diagnosis was associated with inferior response rates and survival compared to those without CL. The results, which were published in the Journal of Hematology & Oncology, suggest that clinicians should consider checking peripheral blood (PB) flow at diagnosis in all newly diagnosed patients with DLBCL. In the retrospective study, adults with de novo DLBCL (diagnosed in or after 2010) who had received anthracycline-based chemotherapy in the first-line setting were grouped into the categories CL-positive (n=85, 15%) and CL- (n=503, 85%) based on PB immunophenotyping, where CL was defined as detectable clonally restricted B-cells that matched the actual or expected B-cell immunophenotype of DLBCL. Patients in CL-positive group were younger (67 vs 70 years, P= 0.03) with a…